Reviva Pharmaceuticals Inc. is a clinical stage pharmaceutical company. It engages in developing therapies to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic and inflammatory diseases. The company's lead product candidate includes RP5063, for the treatment of schizophrenia, bipolar disorder and major depressive disorder. Reviva Pharmaceuticals Inc., formerly known as Tenzing Acquisition Corp., is based in NEW YORK.